the effectiveness of anti-cd3 in this immunotherapy model suggests that a similar approach may be taken to immunotherapy of human malignancies , without the requirements for in vitro-generated killer cells or exogenously administered interleukin 2 .
C0086418
human
C0021756
interleukin 2